Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Get Rating) in a report released on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Pulmatrix in a research report on Tuesday, February 7th.

Pulmatrix Trading Down 3.8 %

Shares of PULM stock opened at $3.28 on Monday. Pulmatrix has a fifty-two week low of $3.16 and a fifty-two week high of $7.50. The business’s 50 day moving average price is $3.82 and its 200-day moving average price is $3.80.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Mariner LLC purchased a new stake in shares of Pulmatrix in the 4th quarter worth about $97,000. Citadel Advisors LLC purchased a new stake in shares of Pulmatrix in the 2nd quarter worth about $141,000. Finally, Renaissance Technologies LLC grew its position in shares of Pulmatrix by 7.3% in the 2nd quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,300 shares during the period. 15.69% of the stock is owned by hedge funds and other institutional investors.

Pulmatrix Company Profile

(Get Rating)

Pulmatrix, Inc is a clinical stage biotechnology company engaged in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.